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IDENTIFICATION OF AN INFLAMMATORY PHENOTYPE WITH HIGHER
LIKELIHOOD OF PROGRESSION IN OA: ANALYSIS OF WOMAC PAIN
SUB-QUESTIONS, C3M AND U-CTX-II FROM TWO PHASE 3
RANDOMIZED CLINICAL TRIALS WITH TREATMENT OF
SYMPTOMATIC KNEE OSTEOARTHRITIS
A.C. Bay-Jensen y, I. Byrjalsen y, K. Musa y, A. Bihlet y, P. Alexandersen z,
J.R. Andersen y, B.J. Riis y, C. Christiansen y, M.A. Karsdal y. ,
CSMC021C2301/2 investigatorsyNordic BioSci. A/S, Herlev, Denmark;
zCCBR A/S, Vejle, Denmark
Purpose: There are three main tissues remodeled as part of osteo-
arthritis (OA); cartilage, bone and the synovial membrane, which may
represent separate phenotypes that needs to be treated differently.
Recent data has shown that type II collagen degradation (CTX-II) is a
biomarker of cartilage and subchondral turnover. C3M is a biomarker of
synovial inﬂammation and turnover. It is estimated that about 10-30%
of OA patients have synovitis. The aim of the study was identify dif-
ferent subtypes of OA related to progression.
Methods: Fasting serum (n¼767) and urine (n¼620) samples were
collected at baseline from patients with painful knee OA participating in
the placebo arms of two phase III RCTs (NCT00486434 and
NCT00704847). Serum C3M (MMP-derived type III collagen neo-epit-
ope [Nordic Bioscience, Denmark]) and creatinine-corrected urinary
CTX-II (type II collagen C-terminal telopeptide [IDS PLC, United King-
dom]) were measured. The relationship between the biomarkers and
the 5 WOMAC pain subscale questions of the baseline-reported
WOMAC pain level, using the sum of target and non-target knee, were
analyzed: A; during walking on a ﬂat surface, B; using stairs (up or
down), C; at night while in bed, D; sitting or lying and E; while standing.
Joint space width was analyzed at baseline and after 24month. The data
were analyzed by Spearman’s correlations on log-transformed data and
by backward multiple regression analysis, where WOMAC or radio-
graphic scores were set as the dependent variable and biomarkers, age,
gender and BMI as covariates.
Results: Levels of CTX-II signiﬁcantly correlated withWOMACwith all 5
sub-questions (p<0.01), while level of C3M was correlated with ques-
tion B and E (p<0.05). When adjusting for age, BMI, and gender, CTX-II
remained signiﬁcantly associated with all sub-questions: A) r¼0.20,
p<0.0001; B) r¼0.16, p¼0.0005; C) r¼0.11, p¼0.017; D) r¼0.13,
p¼0.0046; and E) r¼0.17, p¼0.0002. C3M became non-signiﬁcant; B)
r¼0.08, p¼0.063 and E) r¼0.08, p¼0.069. CTX-II was signiﬁcantly cor-
related to the mean JSW of the two knees (r¼-0.17, p<0.0001), whereas
C3M was signiﬁcantly correlated to joint space narrowing of the target
knee (r¼0.11, p¼0.013).
Conclusions: Diagnostically, urinary CTX-II was associated with all
types of pain. Most prominent with WOMAC sub-question A, walking
on a ﬂat surface, which may indicate that CTX-II is related to pain
coming from continuous skeletal load - supported by the strong cor-
relation with JSW and previous data suggestion origins of subchondral
bone turnover and articular cartilage. C3M, which are released in syn-
ovitis, was weakly correlated with B and E, using stairs and standing
still, respectively. C3M was correlated to progression indicating that
patients with elevated C3M and consequently synovial inﬂammation
had a higher likelihood of being a progressor. These biomarkers may
assist in identiﬁcation of the inﬂammation driven OA phenotype, which
needs to be treated different than non-inﬂammatory OA.
79
IMPROVED PHENOTYPE DEFINITIONS OF OA IN GENETIC
ASSOCIATION STUDIES HIGHLIGHT A STRUCTURAL ROLE FOR A
COMMON VARIANT IN LRCH1
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L. Southam y, arcOGEN ConsortiumM. Doherty k, E. Zeggini y,
J. Wilkinson z. yWellcome Trust Sanger Inst., Hinxton, United Kingdom;
zUniv. of Shefﬁeld, Shefﬁeld, United Kingdom; xBiogen Idec, Cambridge,
MA, USA; kUniv. of Nottingham, Nottingham, United Kingdom
Purpose: Osteoarthritis (OA) has a strong genetic component but the
success of previous genetic association studies has been restricted due
to insufﬁcient sample sizes and phenotype heterogeneity. Differences in
ascertainment criteria along with the highly heterogeneous clinical
manifestations of OA have been proposed as likely factors behind the
paucity of replication for genetic determinants of OA. The aim of our
study is to identify hip OA susceptibility variants by examining a set ofmore homogeneous, radiographically-derived OA endophenotypes
relating to speciﬁc anatomic pattern of joint involvement.
Methods: Hip OA subjects comprised in total 2,118 unrelated individuals
of European ancestry from the arcOGEN genome-wide association study
(GWAS). Inclusion criteriawere radiographic evidence of hip OA (Kellgren
Lawrence (KL)  2) and secondly, a set of minimum radiographic
requirements deﬁned as an antero-posterior (AP) view of the degenerate
hip joint. Hip OA pattern was classiﬁed using standard photographic
atlases as superior, axial, medial and concentric joint space narrowing.
1,817 cases had GWAS data on Illumina 610k and 301 cases had GWAS
data on the HumanOmniExpress platform. We used 6,500 population-
based, publically-available controls from the UK. Following 1000
Genomes-based imputation and stringent quality control we carried out
association analyses at ~7million variants using the score test under an
additive model and meta-analyses with the ﬁxed-effects model. We car-
ried out 2 types of association analyses: GWAS meta-analysis within OA
cases by comparing i) hip OA cases characterised by axial/medial femoral
head migration vs. all other hip OA cases and conversely hip OA cases
characterised by superior femoral head migration vs. all other hip OA
cases; and ii) GWAS of 1,817 hip OA cases stratiﬁed by anatomic pattern of
joint involvement against publically-available controls.
Results: In theGWASmeta-analysis carriedout acrossOAcaseswithaxial/
medial femoral head migration vs. all other hip OA cases the most sig-
niﬁcant association was observed for rs754106 in intron 1 of the LRCH1
gene (for allele T OR[CIs]¼1.46[1.26-1.68]; p¼2.9x10-7). Adjustment for
genderdidnot attenuate the signal (p¼5.7x10-6). Evidence for association
was strong and consistent across bothGWASsetsdespite the small sample
size of the second study (p¼1.1x10-5, N¼425/1392; p¼0.004, N¼76/225).
Conversely in the GWAS meta-analysis carried out across OA cases with
superior femoral head migration vs. the rest (N¼1469/647) rs754106 is
also the most signiﬁcant locus (p¼1.1x10-7) but the T allele is protective
(OR¼0.7). In the association analysis of hip OA patients with axial/medial
femoral head migration vs population-based controls we still ﬁnd strong
evidence for association at rs754106 (p¼0.00015, OR 1.31[1.13-1.5]) but
when we analyse all hip OA cases together vs. the same control set the
signal is fully attenuated (p¼ 0.89).
Rs754106 is in intron 1 of Leucine-Rich Repeats And Calponin Homology
(CH) Domain Containing 1 (LRCH1/CHDC1) gene. Genetic associations
with knee OA at variants spanning intron 1 of LRCH1 were previously
reported but the most signiﬁcant association was observed at rs912428
(for allele T OR[CIs]¼1.44[1.18-1.79]; p<5x10-4, N¼1978/1798) which is
located 15kb away from rs754106 (D’¼1, r2¼0.242). Similar trends in
allele frequencies were observed for samples with hand and hip OA but
were not signiﬁcant. Subsequent publications examining the role of this
variant in knee or hip OA yielded conﬂicting results while a synthesis of
genetic association studies to date reported an OR of 1.17 with nominal
signiﬁcance and moderate heterogeneity. Our ﬁndings indicate that the
paucity of replication at this locus stems from the differences between
prevalence of pattern of joint involvement in the different cohorts.
Conclusions: By partitioning the hip OA phenotype according to speciﬁc
anatomic pattern of joint involvement we detect a common variant in
LRCH1 and highlight the structural role of this gene in OA. We conclude
that in a highly heterogeneous disease like OA precise phenotype deﬁ-
nition is crucial for empowering the detection and replication of OA
susceptibility loci and can provide important insights into the speciﬁc
processes of OA.
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JOINT RELATED NEUROPATHIC PAIN IS ASSOCIATED WITH LOSS OF
JOINT SPECIFIC FUNCTION AND QUALITY OF LIFE WITHIN HIP AND
KNEE OSTEOARTHRITIS PATIENTS
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S.K. Bulstra y, I. van den Akker-Scheek y, M. Stevens y. yUniv. Med. Ctr.
Groningen, Groningen, Netherlands; zMed. Ctr. Leeuwarden,
Leeuwarden, Netherlands; xMartini Hosp. Groningen, Groningen,
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Purpose: In the past decade it became clear that Osteoarthritis (OA)-pain
is not solely nociceptive-driven. Changes within the peripheral and
central nervous system are probably accountable for accessory pain
ampliﬁcation and sensitization. It is believed that central sensitisation
(CS) in combination with peripheral nerve disruption may manifest in
OA-painwith neuropathic features. Based on previous studies it’s known
that about 20-37% of the hip/knee OA patients possess a possible or likely
neuropathic pain (NP) phenotype (painDETECT-score >12). As known,
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of life. To date, it is unclear if NP alone, as a reﬂection of CS is associated
with los of (joint speciﬁc) function and quality of life in patients with hip
or knee OA. The primary aimof this study is therefore; to investigate if NP
is associated with loss of joint speciﬁc patient-centered functional out-
comes and Health Related Quality of life (HRQOL). The secondary aim is
to investigate the relationship between NP and centrally mediated
symptoms (mood, fatigue, sleep quality) and symptoms associated with
CS (widespread pain, illness burden, pain intensity at rest).
Methods: 299 adult primary OA-patients (139 hip-OA, 160 knee-OA)
completed a questionnaire survey bymail. The survey involved questions
about demographic characteristics, OA-pain duration, previous joint
surgery, widespread pain and comorbidities. Subsequently, themodiﬁed-
painDETECT questionnaire (mPDQ; to measure NP), the Knee or Hip
injury and Osteoarthritis Outcome Score (KOOS/HOOS; to measure joint
speciﬁc patient-centered functional outcomes), the Short Form-36 (SF-
36; to measure HRQOL), a joint pain Numeric Rating Scale, a Visual Ana-
logue Scale for joint pain at rest and the Pittsburgh Sleep Quality Index
were administered. Patients were grouped based on their mPDQ-score,
the ﬁrst group (n¼184) involved patients with a nociceptive pain phe-
notype (mPDQ score 12), the second group (n¼115) represented a
possible or likely neuropathic pain phenotype (mPDQ score >12).
Differences between groups were analyzed in case of continues varia-
bles by means of an independent samples t-test (non-parametric
equivalent in case of skewness). For non-continues data a Chi-square or
a Fisher’s exact test was used. A p-value of <0.05 is considered stat-
istically signiﬁcant.
Results: Ninety-two percent of the mPDQ-scores were non-zero and
38.5% of the total population corresponding to a possible or likely NP-
phenotype (hip-OA: 34.5%; knee-OA: 41.9%). The NP-group scored sig-
niﬁcantly higher on bodymass index (BMI), pain intensity, duration and
pain medication usage. None of the patients used non conventional
centrally acting pain medication. No signiﬁcant differences were
observed based on the presence of previous joint surgery. After
adjusting for relevant covariates like; sex, age, BMI, pain intensity and
pain duration: possible or likely NP was signiﬁcantly associated with
loss of joint speciﬁc outcomes on all 5 subscales of the KOOS/HOOS
(mean difference 9.8 points). This goes along with signiﬁcant loss of
HRQOL on the SF-36 dimensions “Physical Functioning” and “Bodily
Pain”. Furthermore, the NP phenotype was to a large extend sig-
niﬁcantly associated (adjusted for sex, age, BMI) with centrally medi-
ated symptoms (mood, p<0.05; fatigue, p<0.05; sleep quality, p¼0.062)
and features associated with CS (widespread pain, p<0.001; illness
burden, p<0.075; pain at rest, p<0.001).
Conclusions: The results indicate that NP -independent from pain
intensity and pain duration- is mainly associated with clinical relevant
loss of the physical (hip/knee speciﬁc) and functional aspects of HRQOL.
Due to the high prevalence of NP in OA-patients and the found asso-
ciation with centrally mediated symptoms and possible CS; it seems to
be justiﬁed to treat NP-patients more speciﬁcally with non-conven-
tional centrally acting pain medication.
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GENETIC VARIANTS IN THE SUPT3H-RUNX2 LOCUS CONFER
SUSCEPTIBILITY FOR BONE AND CARTILAGE RELATED DISORDERS
VIA LONG-RANGE REGULATION OF RUNX2
C.G. Boer y, R. Narcisi y, Y.F. Ramos z, W. den Hollander z, N. Bomer z,
M. C. Castano Betancourt y, A.G. Uitterlinden y, G. van Osch y,
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Purpose: Genome-wide association studies (GWAS) have identiﬁed in
total 6 independent SNPs within the 5’ region of the RUNX2 gene to be
associated to cartilage and bone related phenotypes. We hypothesize
that these SNPs may regulate RUNX2 expression in a time- and differ-
entiation depended manner. In this way, these SNPs might regulate
cartilage and bone differentiation, which result in the multitude of
associations found in this region. Therefore we aim to elucidate the
effect of the identiﬁed SNPs on the regulation and expression of RUNX2
and how these confer susceptibility to cartilage and bone related dis-
orders, such as osteoarthritis and bone mineral density.
Methods: Independent GWAS signals were identiﬁed with linkage dis-
equilibrium (LD) data from the HapMap project and GCTA conditional
joint analysis. SNPs in LD with the GWAS loci were identiﬁed with the
SNAP tool and HaploReg (V2.2, Broad Institute). GWAS SNPs and SNPs inhigh LD were analyzed for enrichment in genomic regulatory regions,
and co-locationwithDNAbinding proteins using data from the ENCODE-
Project, Roadmap epigenetics project, Vista enhancer browser and the
FANTOM5database. In 96 chondrocytes fromexpanded human cartilage
samples for which GWAS-data was available, RUNX2-expression was
measured by RNA-sequencing, afterwhich eQTL analysis was performed
to determine the effect of the SNPs on gene expression. CTCF protein
binding was determined by ChIP-qPCR in human cartilage explants.
Results:Wehave identiﬁed7 SNPs in the5’regionof RUNX2 tobe robustly
associated to height (2 independent loci), bone mineral density (BMD),
osteoarthritis (OA, 2 independent loci),minimal joint spacewidth (mJSW)
and ossiﬁcation of the spine (OPPL) (see ﬁgure 1). Using LD data from the
GWAS signals we observed that 6 GWAS signals were independent of
another, but one of the signals formJSWwas inhigh LDwith that of hipOA
mJSW (r2 >0.8). Next we analysed all GWAS signals for enrichment in
genomic regulatory regions. All independent GWAS signals co-localized
to regions with enrichment of active enhancer markers, H3K4me1,
H3K27ac and DNase1 hypersensitivity enrichment and bi-directional
CAGE reads, in osteoblast and chondrogenic cells.
CTCF (CCCTC-binding factor or 11-zinc ﬁnger protein) is essential for
chromatin organization and gene regulation, its functions include tran-
scription initiationand the formationof long-rangechromatin interactions.
TheBMDassociated SNPswere situated in an area that is involved inCTCF-
binding in osteoablasts. These SNPs are located ~700 kb away from the
RUNX2 promoter, yet they do have a signiﬁcant effect (p<0.05) on RUNX2
gene expression in human cartilage (as quantiﬁed by RNAseq in 96 sam-
ples). In addition,weobservedthatwhenwestimulatedRUNX2expression
in human chondrocytes by TGFb stimulation, there is also an increase in
CTCF binding near the RUNX2 promoter. These results suggest that CTCF
binding may play a role in the regulation of RUNX2 gene expression.
Conclusions:We have shown that variants in the SUPT3H-RUNX2 locus
associated to cartilage and bone phenotypes are located in potential gene
regulatory regions, and effect RUNX2 gene expression. We hypothesize
that the SNPs are localized in long-range enhancers which, mediated by a
CTCF chromatin-loop to the RUNX2 promoters, regulate RUNX2 gene
expression in a time-and differentiation dependent manner during car-
tilage and bone development. Future studies will further investigate the
chromatin architecture of the SUPT3H-RUNX2 locus.
Figure 1. SNPs found in GWAS located in the SUPT3H-RUNX2 locus are
associated to bone and cartilage phenotypes.
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METHYLATION OF CARTILAGE DNA IS A MEDIATOR OF GENETIC RISK
AT SEVERAL OA SUSCEPTIBILITY LOCI
M.D. Rushton, L.N. Reynard, D.A. Young, C. Shepherd, R. Darlay,
H.J. Cordell, J. Loughlin. Newcastle Univ., Newcastle upon Tyne, United
Kingdom
Purpose: Replicated OA genetic risk loci are now emerging through the
use of powerful case-control association studies. The analysis of the
epigenetics of OA has also received considerable attention in the last few
years, particularly CpG methylation in cartilage chondrocyte genomic
DNA. The vast majority of OA risk loci reported to date do not contain
amino-acid substitution polymorphisms that can account for the asso-
ciation signal, implying that OA risk alleles act by modulating gene
expression rather than by changing protein sequence. DNAmethylation
is a mechanism used by the cell to regulate gene expression and DNA
methylation is known to mediate genetic risk in several diseases
including rheumatoid arthritis. In this study we assessed whether DNA
methylation is an intermediary of OA genetic risk by correlating geno-
type at OA risk loci with cartilage DNA CpG methylation.
Methods: In the discovery analysis, DNAwas collected from the cartilage
of 110 elderly individuals. Seventy one of thesewere OA knee patients, 20
